BPC-157 + TB-500 2mg Australia — Small Blend Vial
From $29 AUD · ≥98% HPLC purity · third-party COA · ships Australia-wide
What is BPC 2mg + TB 2mg?
BPC 2mg + TB 2mg is a research blend combining the gastric-derived pentadecapeptide BPC 157 with Thymosin Beta-4 fragment (TB-500), each at 2mg. BPC 157 is studied for angiogenesis and tissue-repair signalling, while TB-500 is investigated for actin binding, cell migration and vascular remodelling. The combination is a reference material in regenerative-peptide studies.
Specifications
- From: $29 AUD
- Category: Recovery & Repair
- Form: Lyophilised powder
- Purity: ≥98% HPLC
- Testing: Third-party Certificate of Analysis
- Classification: Research reference material · For Research Use Only
What the research covers
This vial holds two structurally unrelated peptides co-lyophilised into a single cake, nominally 2 mg of BPC-157 and 2 mg of TB-500, 4 mg of peptide in total. It is the smallest of the several strengths at which this pairing is stocked, and its size is the thing that most changes how it should be handled and read.
BPC-157 is a pentadecapeptide, sequence GEPPPGKPADDAGLV, formula C62H98N16O22, molecular weight 1419.5 daltons, described as a partial fragment of a protein identified in human gastric juice. Rodent studies have investigated it in gastrointestinal lesion models and in tendon, ligament, muscle and bone injury models, with proposed mechanisms in the published literature including nitric oxide system modulation, effects on VEGFR2 signalling and interaction with focal adhesion kinase and paxillin signalling. The evidence is overwhelmingly preclinical and concentrated in a small number of research groups. In Australia BPC-157 has a Schedule 4 entry in the Poisons Standard, implemented on 1 June 2024.
Thymosin beta-4, catalogued in UniProt as P62328, is a 43-residue N-terminally acetylated peptide of approximately 4963 daltons and the major intracellular sequestering protein for monomeric G-actin, participating through that role in cytoskeletal regulation and cell migration.
The name TB-500 is used in the supply chain both for full-length thymosin beta-4 near 4963 daltons and for the short Ac-LKKTETQ actin-binding fragment near 889 daltons. Only the analyte identity and observed mass on a per-component assay establish which is present, and at 2 mg the ambiguity has larger proportional consequences than it does at 10 mg.
TXLABS supplies this blend as an analytical reference material for laboratory research only. It is not an approved therapeutic good in Australia and is not supplied for human or veterinary administration.
Reading the certificate
Per-component assay is the whole question for a blend, and a small fill sharpens it. A single combined purity percentage is not a meaningful measurement when a vial contains two different molecules, and at 2 mg per component the absolute quantities are small enough that assay precision and vial-to-vial fill variance both become proportionally larger. The two components separate readily by reversed-phase chromatography and mass spectrometry, since they differ greatly in size and hydrophobicity, so there is no technical obstacle to quantifying each independently. Confirm specifically which TB-500 species the assay identifies, because the full-length protein near 4963 daltons and the fragment near 889 daltons are both sold under that name and represent very different molar amounts at the same mass. Third-party certificates for tested lots are published by TXLABS in the CoA library. This blend is not among them, and the certificate held for the lot supplied is sent on request to support@txlabs.bio.
Storage and handling
Small fills amplify every handling error, and that is the defining characteristic of this vial. A 2 mg plus 2 mg cake is thin and physically small, so a proportionally larger share of the material sits against glass where adsorption losses matter, and residual hold-up on the vial wall after withdrawal is a bigger fraction of the total than it would be in a 20 mg vial. Rinse technique and complete dissolution therefore matter more here than at larger fills. Store the cake at -20 °C, desiccated and dark, and equilibrate the vial sealed to room temperature before opening so that condensation does not wet the powder. Once reconstituted, hold at 2-8 °C in the dark, add diluent gently down the wall, swirl rather than shake, and aliquot before freezing. Full-length thymosin beta-4 is the less stable of the two components and sets the storage terms. Australian summer transit above 40 °C degrades the larger component faster than the smaller, silently shifting the ratio.
Working out concentration
Track concentration per component. This vial holds nominally 2 mg of BPC-157 and 2 mg of TB-500, 4 mg total. Reconstituted with 1 mL of bacteriostatic water it gives 2 mg/mL of each and 4 mg/mL of total peptide; with 2 mL, 1 mg/mL of each and 2 mg/mL total; with 4 mL, 0.5 mg/mL of each and 1 mg/mL total. Note that the 5 mg plus 5 mg and 10 mg plus 10 mg vials of the same pairing give two and a half and five times these figures at the same diluent volume, which is the most common source of error when moving between strengths. The reconstitution calculator handles the arithmetic. Concentration examples only, not a protocol.
How it relates to adjacent compounds
The same pairing is stocked at two larger strengths, 5 mg plus 5 mg and 10 mg plus 10 mg, and both pages treat the per-component certification question from the perspective of a larger fill. Both components are also available individually as BPC-157 and TB-500 in full-length and fragment forms, which is the route to per-component traceability where that matters more than convenience. Choosing between a blend and separate vials is a question of experimental design and record-keeping rather than chemistry, since the molecules are identical either way. These are formulation relationships only and imply nothing about comparative activity.